Lilly announces $72 million investment in diabetes manufacturing in Indianapolis
Eli Lilly announced plans to invest $72 million in an insulin manufacturing project at one of its Indianapolis facilities. The investment will be used to replace an existing insulin vial filling line and allow Lilly to meet growing demand for its insulins - Humalog® (insulin lispro) and Humulin®. October 23, 2017